Italy to India: Syringe Import Trade Route

The Italy to India Syringe corridor is one of India's established pharmaceutical import routes from Italy, with 44 shipments documented worth a combined $314.2M USD. The route is dominated by NOVARTIS PHARMA AG , which alone accounts for roughly 78% of all import value, reflecting the consolidated nature of Italy's syringe export sector.

Across 13 active Italy suppliers, the average shipment value stands at $7.1M USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 79% of all shipments, consistent with syringe's non-urgent bulk-order profile.

Shipment activity peaks during October–December, with an average transit time of 17 days port-to-port. The route has recorded an annual growth rate of 33.2%, placing it at rank #8 among India's top syringe import origins globally.

On the Indian buyer side, key Indian importers include NOVARTIS HEALTHCARE PRIVATE LIMITED , NOVARTIS HEALTHCARE PRIVATE LIMITED, ALMA MEDICAL PRIVATE LIMITED and 6 others. NOVARTIS HEALTHCARE PRIVATE LIMITED is the single largest Indian importer with 10 shipments valued at $308.5M USD.

India's syringe imports from Italy are driven primarily by a handful of large-scale Italy manufacturers. NOVARTIS PHARMA AG with 6 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 13 active exporters signals a competitive but concentrated market — Indian buyers benefit from Italy supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — NOVARTIS PHARMA AG , NOVARTIS PHARMA AG (BASEL) , IBSA FARMACEUTICI ITALIA SRL — together account for 99% of total trade value on this route. The average shipment value of $7.1M USD reflects primarily bulk commercial orders from large pharmaceutical distributors.

Beyond the primary product category, shipments on this route include closely related formulations such as inclisiran solution for injection in pre-filled syringe 284mg/1.5ml 300321 batch-p324021c (tilpazan) and kjx839 284mg/1.5ml prefilled syringe batch 2048563 (foc) (tl/ct/21/000389 date 24/11/2021) , suggesting that Indian buyers tend to consolidate orders across related product lines from the same Italy supplier.

On the buying side, NOVARTIS HEALTHCARE PRIVATE LIMITED is the largest importer with 10 shipments worth $308.5M USD — representing 98% of all syringe imports from Italy on this route. A total of 9 buyers are active on this corridor.